zur Startseite


Veranstalter, Ort

Plain Language Summary of the Innovate Study: Ibrutinib Plus Rituximab Is Well-Tolerated and Effective in People with Waldenström's Macroglobulinemia

Buske, C., A. Tedeschi, J. Trotman, R. García-Sanz, D. MacDonald, V. Leblond, B. Mahe, C. Herbaux, J. V. Matous, C. S. Tam, L. T. Heffner, M. Varettoni, M. L. Palomba, C. Shustik, E. Kastritis, S. P. Treon, J. Ping, B. Hauns, I. Arango-Hisijara, and M. A. Dimopoulos. Future Oncol (Feb 23 2023).
read more ›


Presentations on WM at this year‘s ASH 2013 in New Orleans

from our consortium on:

  • Elevated Von Willebrand Factor Antigen Serum Levels and their association with poor prognosis In patients with symptomatic Waldenstrom’s Macroglobulinemia  (Efstathios Kastritis et al., Athens, Greece)
  • Disease unrelated mortality accounting for differences in survival in patients >75 Years with symptomatic Waldenström’s Macroglobulinemia  (Efstathios Kastritis et al., Athens, Greece)
  • Newest update of the WM2 trial on the efficacy of Bortezomib in patients with advanced Waldenström Macroglobulinemia  (V. Leblond et al., Paris, France)
‹ back